News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
CombinatoRx, Incorporated Cuts IPO Price To $7-$9 Per Share
November 9, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Nov 9 (Reuters) - Biopharmaceutical company CombinatoRx Inc. cut on Wednesday the expected price of the shares in its initial public offering to $7 to $9 per share from $10 to $12 per share.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Podcast
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
April 1, 2026
·
1 min read
·
Heather McKenzie
Mergers & acquisitions
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
March 31, 2026
·
4 min read
·
Annalee Armstrong
Mergers & acquisitions
Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda
March 31, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
After Missing Kezar Buyout in 2024, Tang Returns as CEO of Aurinia With $50M Offer
March 30, 2026
·
2 min read
·
Annalee Armstrong
